Promedior Inc has received FDA fast track designation for their compound – PRM-151 – as a promising, new therapeutic for patients with myelofibrosis. Myelofibrosis is a rare type of chronic leukemia and is characterized by extensive scarring in bone marrow leading to symptoms, such as anemia.
The new designation supports continuing evidence that PRM-151 may be a viable therapy for treating a range of diseases characterized by fibrosis.
Specifically, in preclinical studies, PRM-151 anti-fibrotic activity was validated in multiple fibrotic diseases, including acute and chronic nephropathy, age-related macular degeneration, liver fibrosis, and pulmonary fibrosis.
